HomeCompareSENGF vs PFE

SENGF vs PFE: Dividend Comparison 2026

SENGF yields 6.25% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $6.7K in total portfolio value· pulled ahead in Year 10
10 years
SENGF
SENGF
● Live price
6.25%
Share price
$0.80
Annual div
$0.05
5Y div CAGR
12%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.9K
Annual income
$3,849.44
Full SENGF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SENGF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSENGFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SENGF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SENGF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SENGF
Annual income on $10K today (after 15% tax)
$531.25/yr
After 10yr DRIP, annual income (after tax)
$3,272.02/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $19,047.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SENGF + PFE for your $10,000?

SENGF: 50%PFE: 50%
100% PFE50/50100% SENGF
Portfolio after 10yr
$46.2K
Annual income
$15,054.08/yr
Blended yield
32.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SENGF
No analyst data
Altman Z
2.4
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SENGF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSENGFPFE
Forward yield6.25%6.13%
Annual dividend / share$0.05$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12%13.2%
Portfolio after 10y$42.9K$49.6K
Annual income after 10y$3,849.44$26,258.71
Total dividends collected$18.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SENGF vs PFE ($10,000, DRIP)

YearSENGF PortfolioSENGF Income/yrPFE PortfolioPFE Income/yrGap
1$11,400$700.00$9,153$693.39+$2.2KSENGF
2$13,033$835.29$8,593$849.25+$4.4KSENGF
3$14,945$999.59$8,336$1,066.78+$6.6KSENGF
4$17,191$1,199.78$8,437$1,384.80+$8.8KSENGF
5$19,839$1,444.57$9,013$1,875.40+$10.8KSENGF
6$22,973$1,744.98$10,306$2,680.72+$12.7KSENGF
7$26,696$2,115.04$12,820$4,101.38+$13.9KSENGF
8$31,137$2,572.67$17,673$6,826.70+$13.5KSENGF
9$36,458$3,140.90$27,543$12,591.86+$8.9KSENGF
10← crossover$42,859$3,849.44$49,560$26,258.71$6.7KPFE

SENGF vs PFE: Complete Analysis 2026

SENGFStock

SINOPEC Engineering (Group) Co., Ltd., together with its subsidiaries, provides engineering, procurement, and construction (EPC) contracting services in the People's Republic of China, the Kingdom of Saudi Arabia, Kuwait, Russia, Malaysia, and internationally. It operates through four segments: Engineering, Consulting and Licensing; EPC Contracting; Construction; and Equipment manufacturing. The Engineering, Consulting and Licensing segment offers design, consulting, research and development, feasibility studies, and compliance certification services. The EPC Contracting segment provides integrated engineering, procurement, construction, maintenance, and project management services. The Construction segment offers infrastructure for oil refining and chemical industries, oil and gas storage, pipelines transportation, construction, renovation, expansion, repair and maintenance services, and large equipment lifting, as well as transportation services in construction projects. The Equipment Manufacturing segment designs, develops, manufactures, and sells equipment and spare parts for oil refining and chemical facilities. The company also provides technical, and equipment selling and leasing services, as well as medicine, pesticide, and chemical research services. The company serves petrol refining, chemical engineering, aromatics, coal chemicals, inorganic chemicals, pharmaceutical chemicals, clean energy, storage and transportation facilities, environmental protection, energy saving, and other industry sectors. The company is headquartered in Beijing, China. SINOPEC Engineering (Group) Co., Ltd. is a subsidiary of China Petrochemical Corporation.

Full SENGF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SENGF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SENGF vs SCHDSENGF vs JEPISENGF vs OSENGF vs KOSENGF vs MAINSENGF vs JNJSENGF vs MRKSENGF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.